Journal: eLife

Article Title: Single-cell glycomics analysis by CyTOF-Lec reveals glycan features defining cells differentially susceptible to HIV

doi: 10.7554/eLife.78870

Figure Lengend Snippet:

Article Snippet: Antibody , Anti-Human CD134/OX40 (ACT35) (Mouse, Monoclonal) , Fluidigm , Cat# 3158012B , CyTOF (1:25).

Techniques: Recombinant, Plasmid Preparation, Software

Journal: STAR Protocols

Article Title: A protocol for high-throughput screening for immunomodulatory compounds using human primary cells

doi: 10.1016/j.xpro.2023.102405

Figure Lengend Snippet:

Article Snippet: CD134 (OX40) Antibody, anti-human, APC, REAfinityTM (Clone- REA621) , Miltenyi Biotec , Order Number: 130-122-227.

Techniques: Recombinant, Sterility, Modification, Staining, Saline, Multiplex Assay, Software

Journal: Frontiers in Immunology

Article Title: Polyfunctional T cells and unique cytokine clusters imprint the anti rAAV2/rAAV9 vector immune response

doi: 10.3389/fimmu.2024.1450524

Figure Lengend Snippet: Used antibodies with respective conjugations (conj.) and dilutions for the flow-cytometric analyses.

Article Snippet: CD134 , PE-Vio770 , 1:50 , REA621 , 130-120-723 , Miltenyi.

Techniques:

Journal: Clinical and Experimental Immunology

Article Title: Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus

doi: 10.1111/cei.13073

Figure Lengend Snippet: Expression of co‐stimulatory and major histocompatibility complex (MHC) class II molecules in natural killer (NK) cells from healthy volunteers and systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 29) and healthy controls (n = 29) were immunostained for CD3, CD56, CD80, CD86, CD134 and human leucocyte antigen D‐related (HLA‐DR). Co‐stimulatory molecules and HLA‐DR were analysed from the CD3–CD56+ subset. Left and middle panel in (a–d). Dot‐plots from one healthy control and one SLE patient are shown. Numbers represent the percentage of CD80, CD86, CD134 or HLA‐DR‐positive cells from the CD3–CD56+ population. The cut‐offs for background fluorescence were based on isotype‐matched immunoglobulin (Ig)‐negative controls and fluorescence minus one (FMO) strategy. Right panel in (a–d). Analysis of the expression of CD80, CD86, CD134 or HLA‐DR in the CD3–CD56+ subset from SLE patients and healthy controls. Data are represented as the median and the interquartile range. *P < 0·05; **P < 0·005; ***P < 0·0001.

Article Snippet: Characteristics clinic and demographics of systemic lupus erythematosus (SLE) patients table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Drug combination Number of patients Methotrexate + anti‐malarial 3 Methotrexate + prednisone + cyclosporin Methotrexate + prednisone 11 Prednisone + azathioprine Methotrexate + prednisone + azulfidine Methotrexate + prednisone + anti‐malarial 6 Methotrexate + prednisone + anti‐malarial + cyclophosphamide Prednisone + anti‐malarial Anti‐malarial 5 Prednisone + anti‐malarial + azathioprine Anti‐malarial + mycophenolate mofetil Prednisone + anti‐malarial + cyclophosphamide + mycophenolate mofetil Methotrexate + prednisone + azathioprine Mycophenolate mofetil methotrexate + prednisone + anti‐malarial + mycophenolate mofetil Prednisone Mycophenolate mofetil + tacrolimus Methotrexate 4 Open in a separate window Combination therapy schemes used in systemic lupus erythematosus (SLE) patients Antibodies The following monoclonal anti‐human antibodies were used: anti‐human CD3 labelled with peridinin chlorophyll (PerCP), anti‐human NKp46‐phycoerythrin (PE), anti‐human NKG2D‐PE, anti‐human CD107a [lysosomal‐associated membrane protein 1 (LAMP‐1)] coupled to PE/cyanin 7 (Cy7), anti‐human CD11c‐PerCP/Cy5 and anti‐human human leucocyte antigen D‐related (HLA‐DR) coupled to allophycocyanin (APC)/Cy7 (BioLegend, San Diego, CA), anti‐human CD56 labelled with APC, anti‐human ILT2‐PE, anti‐human CD80‐fluorescein isothiocyanate (FITC), anti‐human CD86 coupled to PE and anti‐human CD134 (OX40)‐PE, anti‐HLA‐DR‐PE (eBioscience, San Diego, CA, USA), anti‐human CD161‐PE (BD Biosciences, San José, CA, USA), anti‐human CD159a/NKG2A labelled with phycoerythrin [magnetic affinity cell sorting (MACS); Miltenyi Biotec, Bergisch Gladbach, Germany] and anti‐human NKG2C PE‐conjugated anti‐human NKp30‐PE (R&D Systems, Minneapolis, MN, USA).

Techniques: Expressing, Immunopeptidomics, Control, Fluorescence